The company claims that with 62,000 physicians treating a population of nearly 34 million people, Canada represents a significant market. Cardioscan’s optional telemedicine capabilities are well suited for the Canadian healthcare system, which has embraced telemedicine as a core initiative.

The introduction of Cardioscan heart sound analysis software into the market will provide benefits during face-to-face patient encounters and allow healthcare providers to extend the use of auscultation (listening with a stethoscope) to situations and environments where face-to-face encounters are not always feasible.

This clearance allows the company to begin marketing Cardioscan and the accompanying stethoscope in Canada.

John Kallassy, CEO of Zargis, said: “We’ve been seeing increasing interest among the Canadian medical community in Cardioscan and its telemedicine functionality, which is predictable given Canada’s geography and the nature of its population distribution.”